Analyst Reco. SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
42.38 ^USD	-1.00%		-5.49%	+16.11%

May. 23	SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	CI
May. 15	Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating	May. 02	MT
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	Mar. 06	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	Mar. 06	MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating	Feb. 26	MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating	Feb. 07	MT
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating	Jan. 25	MT
Goldman Sachs Raises Price Target on SpringWorks Therapeutics to $52 From $47, Maintains Buy Rating	Nov. 29	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $73 From $64, Keeps Buy Rating	Nov. 29	MT
HC Wainwright Raises SpringWorks Therapeutics' Price Target to $64 From $52, Buy Rating Kept	Nov. 28	MT
HC Wainwright Adjusts SpringWorks Therapeutics' Price Target to $52 From $58, Maintains Buy Rating	Nov. 20	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $58 From $66, Maintains Buy Rating	Nov. 09	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $66 From $105, Keeps Buy Rating	23-08-07	MT
Goldman Sachs Adjusts Price Target on SpringWorks Therapeutics to $49 From $43, Maintains Buy Rating	23-07-20	MT
Barclays Adjusts Price Target on SpringWorks Therapeutics to $41 From $55, Keeps Overweight Rating	23-04-28	MT
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $57 From $53, Maintains Overweight Rating	23-03-07	MT
HC Wainwright Adjusts SpringWorks Therapeutics Price Target to $105 From $99, Maintains Buy Rating	23-03-07	MT
Goldman Sachs Raises SpringWorks Therapeutics' Price Target to $45 From $40, Maintains Buy Rating	23-01-26	MT
BofA Securities Starts SpringWorks Therapeutics at Buy With $45 Price Target	22-12-01	MT
Wedbush Cuts SpringWorks Therapeutics' Price Target to $45 From $52, Keeps Outperform Rating	22-11-23	MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $99 From $103, Maintains Buy Rating	22-11-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Analyst Reco.

Filters